Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 3/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349396 | 0.89 | PRKAA2 (0.45) | KMT2AKCNH2PRKAA2MCHR1ALDH1A1 | |
| SCHEMBL4353675 | 0.89 | RORC (0.44) | GPR119RORCSCN1ASCN8AKCNH2 | |
| SCHEMBL4351876 | 0.88 | FAAH (0.45) | RORCALDH1A1 | |
| SCHEMBL4346924 | 0.87 | GRIN1 (0.43) | KMT2ARORCMCHR1ALDH1A1 | |
| SCHEMBL4352545 | 0.87 | S1PR5 (0.44) | PRKAA2ALDH1A1 | |
| SCHEMBL4345654 | 0.86 | RORC (0.43) | KCNJ1GPR119RORCKCNH2MCHR1 | |
| SCHEMBL4533849 | 0.85 | MCHR1 (0.42) | GPR119KCNH2PRKAA2MCHR1 | |
| SCHEMBL4355711 | 0.85 | ACACB (0.41) | KCNJ1GPR119RORCOPRM1ALDH1A1 | |
| SCHEMBL14403832 | 0.84 | KCNH2 (0.41) | GBA1KCNJ1GPR119RORCKCNH2 | |
| SCHEMBL4348326 | 0.84 | KCNH2 (0.50) | GPR119KCNH2PRKAA2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010485-B1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2012-10-17 | — | — | EP | claimed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | claimed |
| EP-2010485-B1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| WO-2007116230-A1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | GPR119, GPR39, GIPR | GBA1 2272/4885KCNJ1 742/4885KMT2A 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.